Should I buy or sell BioVie stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIVI shares. View BIVI analyst ratings or view top-rated stocks .

What is BioVie's stock price target for 2024?

2 brokerages have issued 1-year price objectives for BioVie's stock. Their BIVI share price targets range from $5.00 to $11.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 1,538.0% from the stock's current price. View analysts price targets for BIVI or view top-rated stocks among Wall Street analysts .

How have BIVI shares performed in 2024?

BioVie's stock was trading at $1.26 at the beginning of 2024. Since then, BIVI stock has decreased by 61.2% and is now trading at $0.4884. View the best growth stocks for 2024 here .

When is BioVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BIVI earnings forecast .

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10.

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BIVI

BioVie (BIVI) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free BIVI Stock Alerts

$0.49

+0.02 (+4.27%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.46
▼
$0.51
50-Day Range: $0.47
▼
$1.89
52-Week Range: $0.45
▼
$8.69

Volume: 1.38 million shs
Average Volume: 2.21 million shs
Market Capitalization: $19.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get BioVie alerts:

BioVie MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,538.0% Upside
$8.00 Price Target
Short Interest: Healthy
3.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

Medical Sector

755th out of 919 stocks

Pharmaceutical Preparations Industry

332nd out of 405 stocks

3.3

Analyst's Opinion

Consensus Rating
BioVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
BioVie has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.71% of the outstanding shares of BioVie have been sold short.
Short Interest Ratio / Days to Cover
BioVie has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioVie has recently decreased by 3.90%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
BioVie does not currently pay a dividend.
Dividend Growth
BioVie does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIVI.

2.0

News and Social Media Coverage

News Sentiment
BioVie has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for BioVie this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added BioVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioVie insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of BioVie is held by insiders.
Percentage Held by Institutions
Only 4.59% of the stock of BioVie is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BioVie is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioVie is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioVie has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About BioVie Stock (NASDAQ:BIVI)

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BIVI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIVI Stock News Headlines

April 18, 2024 | globenewswire.com

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 18, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)

March 17, 2024 | stockhouse.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

March 16, 2024 | stockhouse.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

March 16, 2024 | ca.finance.yahoo.com

BIVI Oct 2024 1.500 put

March 15, 2024 | finance.yahoo.com

BIVI Jul 2024 3.500 put

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 15, 2024 | finance.yahoo.com

BIVI Apr 2024 5.000 put

March 15, 2024 | prnewswire.com

Shareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI

March 14, 2024 | prnewswire.com

The Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming Deadline

March 14, 2024 | stockhouse.com

4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

March 13, 2024 | prnewswire.com

BIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud Lawsuit

March 12, 2024 | prnewswire.com

Class Action Filed Against BioVie Inc. (BIVI) - March 19, 2024 Deadline to Join - Contact Levi & Korsinsky

March 11, 2024 | proactiveinvestors.com

BioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summer

March 11, 2024 | globenewswire.com

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

March 11, 2024 | prnewswire.com

BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI

March 9, 2024 | stockhouse.com

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

March 8, 2024 | markets.businessinsider.com

BIOVIE INVESTOR ALERT: Kirby McInerney LLP Alerts BioVie, Inc. (BIVI) Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit

March 7, 2024 | prnewswire.com

Contact The Gross Law Firm by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI)

March 7, 2024 | markets.businessinsider.com

ATTENTION BIOVIE INC. Shareholders: Securities Fraud Lawsuit Filed Against BioVie Inc. (BIVI)

March 6, 2024 | globenewswire.com

BioVie Inc. Announces Closing of Public Offering

March 6, 2024 | prnewswire.com

Contact Levi & Korsinsky by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI)

March 4, 2024 | finance.yahoo.com

BIVI Apr 2024 1.500 put

March 4, 2024 | finance.yahoo.com

BIVI Oct 2024 0.500 put

March 4, 2024 | markets.businessinsider.com

BioVie Announces Pricing Of Its Best Efforts Public Offering - Quick Facts

See More Headlines

Receive BIVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/12/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BIVI
CUSIP: N/A
CIK: 1580149
Web: bioviepharma.com
Phone: (775) 888-3162
Fax: N/A
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $11.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,538.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,260,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -332.18%
Return on Assets: -137.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.47
Quick Ratio: 1.47

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.42 per share
Price / Book: 1.16

Miscellaneous

Outstanding Shares: 39,920,000
Free Float: 38,009,000
Market Cap: $19.50 million
Optionable: Optionable
Beta: 0.79

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Cuong Viet Do M.B.A. (Age 58)
President, CEO & Director
Comp: $1.08M
Ms. Joanne Wendy Kim CPA (Age 69)
CFO, Treasurer & Corporate Secretary
Comp: $397.38k
Dr. Joseph M. Palumbo M.D. (Age 64)
Executive VP of R&D and Chief Medical Officer
Comp: $722k
Mr. Clarence N. Ahlem (Age 69)
Senior Vice President of Operations
Dr. Penelope Markham Ph.D. (Age 58)
Senior Vice President of Liver Disease Program
Ms. Denise Smith
Senior Vice President of Manufacturing & Development
Dr. Christopher L. Reading Ph.D. (Age 76)
Senior Vice President of Alzheimer's Disease Program
Ms. Sarah Overton Hoit (Age 56)
Chief Social Impact Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIVI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioVie stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIVI shares.
View BIVI analyst ratings or view top-rated stocks.
What is BioVie's stock price target for 2024?: 2 brokerages have issued 1-year price objectives for BioVie's stock. Their BIVI share price targets range from $5.00 to $11.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 1,538.0% from the stock's current price.
View analysts price targets for BIVI or view top-rated stocks among Wall Street analysts.
How have BIVI shares performed in 2024?: BioVie's stock was trading at $1.26 at the beginning of 2024. Since then, BIVI stock has decreased by 61.2% and is now trading at $0.4884.
View the best growth stocks for 2024 here.
When is BioVie's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BIVI earnings forecast.

How were BioVie's earnings last quarter?: BioVie Inc. (NASDAQ:BIVI) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10.
How do I buy shares of BioVie?: Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIVI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioVie (BIVI) Stock Price, News & Analysis

BioVie MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BioVie Stock (NASDAQ:BIVI)

BIVI Stock Price History

BIVI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BIVI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™